Chromophobe Renal Cell Carcinoma Aggressiveness and Immuno-oncology Therapy: How to Distinguish the Good One from the Bad One

被引：3
|
作者：
Montironi, Rodolfo [1 ]
Cimadamore, Alessia [1 ]
Ohashi, Riuko [2 ]
Cheng, Liang [3 ]
Scarpelli, Marina [1 ]
Lopez-Beltran, Antonio [4 ]
Moch, Holger [5 ,6 ]
机构：
[1] Polytech Univ Marche Reg, Sch Med, United Hosp, Sect Pathol Anat, Ancona, Italy
[2] Niigata Univ, Fac Med, Histopathol Core Facil, Niigata, Japan
[3] Indiana Univ Sch Med, Dept Pathol & Lab Med, Indianapolis, IN 46202 USA
[4] Fac Med, Dept Pathol & Surg, Cordoba, Spain
[5] Univ Zurich, Dept Pathol & Mol Pathol, Zurich, Switzerland
[6] Univ Zurich Hosp, Zurich, Switzerland
来源：
EUROPEAN UROLOGY ONCOLOGY | 2021年 / 4卷 / 02期
关键词：
UTILITY;
D O I：
10.1016/j.euo.2020.02.011
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：331 / 333
页数：3
相关论文
共 50 条
  • [1] Immuno-oncology therapy associated thromboembolic events in metastatic renal cell carcinoma
    Alhamdani, Zein
    Alberto, Matthew
    Ischia, Joseph
    UROLOGY CASE REPORTS, 2023, 49
  • [2] Complexity of the genomic landscape of renal cell carcinoma: Implications for targeted therapy and precision immuno-oncology
    Sanfrancesco, Joseph M.
    Cheng, Liang
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2017, 119 : 23 - 28
  • [3] The role of nephrectomy in metastatic renal cell carcinoma in the immuno-oncology era
    Wuernschimmel, Christoph
    Nocera, Luigi
    Wenzel, Mike
    Colla Ruvolo, Claudia
    Tian, Zhe
    Karakiewicz, Pierre I.
    BJU INTERNATIONAL, 2021, 128 (04) : 438 - 439
  • [4] Cytoreductive nephrectomy for oligometastatic clear cell renal cell carcinoma in the era of immuno-oncology
    Marandino, Laura
    Mollica, Veronica
    Campi, Riccardo
    CURRENT OPINION IN UROLOGY, 2025, 35 (03) : 301 - 307
  • [5] Comparing Immuno-oncology Combination Therapy With Tyrosine Kinase Inhibitor Monotherapy for Advanced Renal Cell Carcinoma
    Ishikawa, Gaku
    Tamura, Keita
    Tsuchiya, Yoshihiro
    Watanabe, Shunsuke
    Ayana, Takemura
    Asuka, Sano
    Watanabe, Kyohei
    Watanabe, Hiromitsu
    Matsushita, Yuto
    Motoyama, Daisuke
    Otsuka, Atsushi
    Inamoto, Teruo
    ANTICANCER RESEARCH, 2025, 45 (01) : 379 - 386
  • [6] Clinical outcomes and prognostic factors in metastatic nonclear cell renal cell carcinoma treated with immuno-oncology combination therapy
    Toyoda, Shingo
    Fukuokaya, Wataru
    Mori, Keiichiro
    Kawada, Tatsushi
    Katayama, Satoshi
    Nishimura, Shingo
    Maenosono, Ryoichi
    Tsujino, Takuya
    Adachi, Takahiro
    Hirasawa, Yosuke
    Saruta, Masanobu
    Komura, Kazumasa
    Nukaya, Takuhisa
    Yanagisawa, Takafumi
    Takahara, Kiyoshi
    Hashimoto, Takeshi
    Azuma, Haruhito
    Ohno, Yoshio
    Shiroki, Ryoichi
    Araki, Motoo
    Kimura, Takahiro
    Fujita, Kazutoshi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 54 (12) : 1336 - 1342
  • [7] Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors
    Graham, Jeffrey
    Shah, Amishi Y.
    Wells, J. Connor
    McKay, Rana R.
    Vaishampayan, Ulka
    Hansen, Aaron
    Donskov, Frede
    Bjarnason, Georg A.
    Beuselinck, Benoit
    De Velasco, Guillermo
    Iafolla, Marco
    Duh, Mei S.
    Huynh, Lynn
    Chang, Rose
    Zanotti, Giovanni
    Ramaswamy, Krishnan
    Choueiri, Toni K.
    Tannir, Nizar M.
    Heng, Daniel Y. C.
    EUROPEAN UROLOGY ONCOLOGY, 2021, 4 (01): : 102 - 111
  • [8] Soluble Immune Checkpoint Molecules as Predictors of Efficacy in Immuno-Oncology Combination Therapy in Advanced Renal Cell Carcinoma
    Ueda, Kosuke
    Uemura, Keiichiro
    Ito, Naoki
    Sakai, Yuya
    Ohnishi, Satoshi
    Suekane, Hiroki
    Kurose, Hirofumi
    Hiroshige, Tasuku
    Chikui, Katsuaki
    Nishihara, Kiyoaki
    Nakiri, Makoto
    Suekane, Shigetaka
    Ogasawara, Sachiko
    Yano, Hirohisa
    Igawa, Tsukasa
    CURRENT ONCOLOGY, 2024, 31 (04) : 1701 - 1712
  • [9] Persisting challenges in the development of predictive biomarkers for immuno-oncology therapies for renal cell carcinoma
    Kato, Renpei
    Obara, Wataru
    EXPERT REVIEW OF ANTICANCER THERAPY, 2025, 25 (02) : 97 - 103
  • [10] CD 9 and vimentin distinguish clear cell from chromophobe renal cell carcinoma
    Williams, Ariel A.
    Higgins, John P. T.
    Zhao, Hongjuan
    Ljungberg, Borje
    Brooks, James D.
    BMC CLINICAL PATHOLOGY, 2009, 9
12345